Login to Your Account



Deals And M&A NEWS
Horizon Pharma plc is looking to add approved drugs Ravicti (glycerol phenylbutyrate) and Buphenyl (sodium phenylbutyrate) to its orphan drug business by acquiring the outstanding shares of developer Hyperion Therapeutics Inc. for $46 apiece in cash, or approximately $1.1 billion.

There is no doubt that the field of cancer immunotherapy is attracting a great deal of attention from investors and big pharma companies alike these days.

Vical Inc. is moving to expand its infectious disease portfolio by in-licensing a trial-ready antifungal from Astellas Pharma Inc. that could complement a DNA-based cytomegalovirus (CMV) vaccine on which the companies already collaborate.
More Deals And M&A Headlines

Cast Your Vote

Has biotech’s bubble burst?: